Factors such as increasing geriatric population and increasing cases of cardiovascular diseases are increasing the cardiac biomarker diagnostic kits market size. Current clinical trials for identification of novel cardiac biomarkers coupled with increasing fund from public-private organizations for research and development is also expanding the market.
The market is bifurcated into by type, by product, by disease, by type of testing and by region. The troponin I and T segment are expected to show notable cardiac biomarker diagnostic kits market growth owing to its high sensitivity, rapid prediction of outcomes and high specificity. It also offers longer elevation time. All these benefits have resulted in demand for troponin I and T, thus proliferating the market.
Based on product, reagents and kits are expected to dominate the growth of the market. Increasing cases of cardiovascular diseases and the availability of multiple reagents ad kits is driving the growth of the market. In addition, the continuous launch of reliable, faster and new reagents and kits increasing the cardiac biomarker diagnostic kits size.
On the basis of the type of testing, point-of-care testing is expected to control the growth of the market. Point-of-care testing offers various benefits such as enhanced user and patient experience, reduced length of stay and better turnaround times. All these benefits have resulted in rising point-of-care testing procedures. Technological advancements have led in much faster, advances and easy to use devices, thus resulting in expansion of the market.
In terms of disease, myocardial infarction segment is expected to control the growth of the market. The increasing number of patients required for the diagnosis of acute myocardial infarction remains the major factor boosting the growth of the market.
In terms of region, North America is the global front runner of the market. The rise in geriatric population coupled with presence of prominent players is bolstering the market in the region. The increasing incidence of cardiovascular disease coupled with rising adoption of point-of-care diagnostic is expected to accelerate the growth of the market in the region.
Prominent players of the market are
BioMerieux SA, Guangzhou Wondfo Biotech Co., Ltd, Danaher Corporation, Siemens AG, Abbott Laboratories, Alere, Inc., LSI Medience Corporation, Randox laboratories, and Ortho Clinical Diagnostics.